Form 4: RAPT Therapeutics CFO Amends Stock Options
SEC Form 4 Filing
RAPT Therapeutics' Chief Financial Officer, Rodney Young, amended several employee stock options, resulting in the cancellation of old options and the grant of new ones with a lower exercise price.
Summary
- Rodney Young, the Chief Financial Officer of RAPT Therapeutics, amended several of his employee stock options on November 13, 2024.
- These amendments involved the cancellation of existing options and the grant of new replacement options.
- The new options have a lower exercise price of $1.57 per share, compared to the original exercise prices which ranged from $19.53 to $29.05.
- The total number of shares underlying the options remains the same, with 140,000 shares from options originally granted in 2019, 60,000 from 2021, 65,000 from 2022, 68,000 from 2023 and 90,000 from 2024.
- The new options vest monthly over a four-year period from the original vesting commencement dates.
Sentiment
Score: 6
Explanation: The document reflects a routine administrative action regarding stock options. While the lower exercise price is positive for the CFO, it doesn't indicate a significant shift in the company's overall prospects.
Positives
- The amendment of stock options provides the CFO with a lower exercise price, potentially increasing the value of his options.
- The new options maintain the same vesting schedule as the original options.
Industry Context
Stock option amendments are a common practice in the biotech industry to incentivize and retain key personnel. This amendment suggests a potential adjustment to the company's compensation strategy.
Comparison to Industry Standards
- Stock option grants and amendments are a standard practice across the biotech industry, with companies like Amgen, Gilead, and Regeneron also utilizing stock options as part of their compensation packages.
- The specific terms of these options, such as exercise price and vesting schedules, can vary widely based on company performance, stage of development, and individual roles.
- The reduction in exercise price for the RAPT CFO's options is not uncommon, especially in cases where the stock price has declined since the original grant date.
Stakeholder Impact
- The stock option amendment may have a minor positive impact on employee morale, particularly for the CFO.
- The amendment does not have a direct impact on shareholders, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 12/02/2019 | Original grant date of the first set of options that were amended. |
| 01/28/2021 | Original grant date of the second set of options that were amended. |
| 01/01/2021 | Vesting commencement date for the second set of options. |
| 01/28/2022 | Original grant date of the third set of options that were amended. |
| 01/01/2022 | Vesting commencement date for the third set of options. |
| 01/31/2023 | Original grant date of the fourth set of options that were amended. |
| 01/01/2023 | Vesting commencement date for the fourth set of options. |
| 01/31/2024 | Original grant date of the fifth set of options that were amended. |
| 01/01/2024 | Vesting commencement date for the fifth set of options. |
| 11/13/2024 | Date of the stock option amendments. |
| 11/15/2024 | Date of the SEC filing. |
| 12/01/2029 | Expiration date of the first set of amended options. |
| 01/27/2031 | Expiration date of the second set of amended options. |
| 01/27/2032 | Expiration date of the third set of amended options. |
| 01/30/2033 | Expiration date of the fourth set of amended options. |
| 01/30/2034 | Expiration date of the fifth set of amended options. |
Keywords
stock options, employee stock options, RAPT Therapeutics, Rodney Young, CFO, option amendment, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.